KALARIS THERAPEUTICS (KLRS) 8-K Summary

Kalaris Therapeutics, Inc. announced a key executive change via Form 8-K filed October 28, 2025.

Management Appointment

• Matthew Gall appointed Chief Financial Officer and Treasurer, effective November 3, 2025.
• He is designated as the Company’s principal financial officer.
• Brett Hagan steps down as principal financial officer but remains SVP, Finance and Chief Accounting Officer.

Compensation Details

• Base Salary: $485,000 annualized.
• Bonus: Target incentive bonus up to 40.0% of base salary.
• Equity Grant: Incent